Arts & Sciences Brown School McKelvey School of Engineering School of Medicine Weekly Publications

WashU weekly Neuroscience publications

"Focused Ultrasound-enabled Brain Tumor Liquid Biopsy" (2018) Scientific Reports

Focused Ultrasound-enabled Brain Tumor Liquid Biopsy
(2018) Scientific Reports, 8 (1), art. no. 6553, . 

Zhu, L.a , Cheng, G.a , Ye, D.b , Nazeri, A.c , Yue, Y.b , Liu, W.d , Wang, X.d , Dunn, G.P.e f , Petti, A.A.g h , Leuthardt, E.C.a b e i j , Chen, H.a d

a Department of Biomedical Engineering, Washington University in St. Louis, Saint Louis, MO, United States
b Department of Mechanical Engineering and Materials Science, Washington University in St. Louis, Saint Louis, MO, United States
c Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, MO, United States
d Department of Radiation Oncology, Washington University School of Medicine, Saint Louis, MO, United States
e Department of Neurosurgery, Washington University School of Medicine, Saint Louis, MO, United States
f Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, Saint Louis, MO, United States
g McDonnel Genome Institute, Washington University School of Medicine, Saint Louis, MO, United States
h Department of Medicine, Washington University School of Medicine, Saint Louis, MO, United States
i Department of Neuroscience, Washington University School of Medicine, Saint. Louis, MO, United States
j Center for Innovation in Neuroscience and Technology, Washington University School of Medicine, Saint Louis, MO, United States

Abstract
Although blood-based liquid biopsies have emerged as a promising non-invasive method to detect biomarkers in various cancers, limited progress has been made for brain tumors. One major obstacle is the blood-brain barrier (BBB), which hinders efficient passage of tumor biomarkers into the peripheral circulation. The objective of this study was to determine whether FUS in combination with microbubbles can enhance the release of biomarkers from the brain tumor to the blood circulation. Two glioblastoma tumor models (U87 and GL261), developed by intracranial injection of respective enhanced green fluorescent protein (eGFP)-transduced glioblastoma cells, were treated by FUS in the presence of systemically injected microbubbles. Effect of FUS on plasma eGFP mRNA levels was determined using quantitative polymerase chain reaction. eGFP mRNA were only detectable in the FUS-treated U87 mice and undetectable in the untreated U87 mice (maximum cycle number set to 40). This finding was replicated in GL261 mice across three different acoustic pressures. The circulating levels of eGFP mRNA were 1,500-4,800 fold higher in the FUS-treated GL261 mice than that of the untreated mice for the three acoustic pressures. This study demonstrated the feasibility of FUS-enabled brain tumor liquid biopsies in two different murine glioma models across different acoustic pressures. © 2018 The Author(s).

Document Type: Article
Source: Scopus

"Use of Pipeline™ embolization device for the treatment of traumatic intracranial pseudoaneurysms: Case series and review of cases from literature" (2018) Clinical Neurology and Neurosurgery

Use of Pipeline™ embolization device for the treatment of traumatic intracranial pseudoaneurysms: Case series and review of cases from literature
(2018) Clinical Neurology and Neurosurgery, 169, pp. 154-160. 

Sami, M.T.a , Gattozzi, D.A.a , Soliman, H.M.b e , Reeves, A.R.c , Moran, C.J.d , Camarata, P.J.a , Ebersole, K.C.a

a Department of Neurosurgery, University of Kansas Medical Center, Mail Stop 3021, Kansas City, KS, United States
b Department of Neurosurgery, Medical College of Wisconsin, Milwaukee, WI, United States
c Department of Radiology, University of Kansas, Medical Center, 3901 Rainbow Boulevard, Kansas City, KS, United States
d Department of Radiology, Washington University School of Medicine, Barnes-Jewish Hospital Mallinckrodt Institute of Radiology, 510 South Kingshighway Boulevard, St. Louis, MO, United States
e Present Address: 9200 W. Wisconsin Ave, Milwaukee, WI, United States

Abstract
Objective: Intracranial traumatic pseudoaneurysms (PSA) are a rare but dangerous subtype of cerebral aneurysm. Reports documenting use of flow-diverting stents to treat traumatic intracranial PSAs are few and lack long-term follow-up. To our knowledge, this is the largest case-series to date demonstrating use of Pipeline Endovascular Device (PED) for traumatic intracranial PSAs. Patients and Methods: Retrospective review of 8 intracranial traumatic PSAs in 7 patients treated using only PED placement. Patients were followed clinically and angiographically for at least 6 months. Results: Seven patients with a mean age of 37 years were treated for 8 intracranial pseudo-aneurysms between 2011–2015. Six aneurysms were the result of blunt trauma; 2 were from iatrogenic injury during transsphenoidal surgery. Mean clinical and angiographic follow-up in surviving patients was 15.2 months. In patients with angiographic follow-up, complete occlusion was achieved in all but one patient, who demonstrated near-complete occlusion. No ischemic events or stent-related stenosis were observed. One patient developed a carotid-cavernous fistula after PED, which was successfully retreated with placement of a second PED. There were two mortalities. One was due to suspected microwire perforation remote from the target aneurysm resulting in SAH/IPH. The other was due to a traumatic SDH and brainstem hemorrhage from an unrelated fall during follow-up interval. Conclusions: Use of PED for treatment of intracerebral PSAs following trauma or iatrogenic injury showed good persistent occlusion, and acceptable complication rate for this high-risk pathology. Risks of this procedure and necessary antiplatelet therapy require appropriate patient selection. Larger prospective studies are warranted. © 2018 Elsevier B.V.

Author Keywords
Iatrogenic;  Internal carotid artery (ICA);  Pipeline™ embolization device (PED);  Pseudoaneurysm (PSA);  Skull Base fracture;  Subarachnoid hemorrhage (SAH);  Trauma

Document Type: Article
Source: Scopus

"Risk of readmission for suicide attempt after epilepsy hospitalization" (2018) Epilepsy and Behavior

Risk of readmission for suicide attempt after epilepsy hospitalization
(2018) Epilepsy and Behavior, 83, pp. 124-130. 

Xu, K.Y.a b , Rossi, K.C.c , Kim, A.M.d , Jetté, N.c e , Yoo, J.Y.c , Hung, K.d , Dhamoon, M.S.c

a Icahn School of Medicine at Mount Sinai, MD/MPH Program, United States
b Washington University School of Medicine in St. Louis, Department of Psychiatry, United States
c Icahn School of Medicine at Mount Sinai, Department of Neurology, United States
d Icahn School of Medicine at Mount Sinai, Department of Psychiatry, United States
e Icahn School of Medicine at Mount Sinai, Department of Population Health Science and Policy, United States

Abstract
Objective: The objective of this study was to examine if epilepsy admissions are associated with a higher readmission risk for suicide attempt, independent of psychiatric comorbidity, compared with index admissions for other medical causes. Methods: The Nationwide Readmissions Database is a nationally representative dataset containing data from roughly 15 million hospital discharges. Analysis of International Classification of Disease Clinical Modification 9 (ICD-9-CM) codes in the year 2013 revealed 58,278 index admissions for epilepsy; this group was compared with admissions for stroke (N = 215,821) and common medical causes (N = 973,078). Ninety-day readmission rates for suicide attempts were calculated. Cox regression tested for associations between admission type and suicide attempt readmissions up to 1 year following index admission. Results: There were 402/100,000 readmissions for suicide attempt within 90 days from index admission in the group with epilepsy; 43/100,000 in the stroke group; and between 37 and 89/100,000 in the medical group. Unadjusted hazard ratios (HR) for suicide readmissions within 1 year in the group with epilepsy compared with the stroke group were 9.61 (95% confidence interval (CI): 7.69–11.90, p < 2.0 × 10− 16) and 5.02 compared with the medical group (95% CI: 4.40–5.73, p < 2.0 × 10− 16). The HR for readmission in the group with epilepsy, after adjustment for sociodemographic and psychiatric variables, were elevated at 4.91 compared with the stroke group (95% CI: 3.83–6.27, p < 2.0 × 10− 16), and 2.66 compared with the medical group (95% CI: 2.32–3.05, p < 2.0 × 10− 16). Conclusion: Independent of psychiatric comorbidities, epilepsy admissions may be independently associated with more than a threefold increased risk of hospital readmission for suicide in the year following index admission in comparison with patients recently hospitalized because of stroke or other common medical disorders. © 2018 Elsevier Inc.

Author Keywords
Epilepsy;  Hospitalizations;  Readmissions;  Seizures;  Suicide

Document Type: Article
Source: Scopus

"What We Have Learned From the Ocular Hypertension Treatment Study" (2018) American Journal of Ophthalmology

What We Have Learned From the Ocular Hypertension Treatment Study
(2018) American Journal of Ophthalmology, 189, pp. xxiv-xxvii. 

Gordon, M.O., Kass, M.A.

Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St. Louis, Missouri, United States

Abstract
Purpose: To identify results from the Ocular Hypertension Study that can aid patients and clinicians to make evidence-based decisions about the management of ocular hypertension. Design: Perspective. Results: At 60 months, the cumulative frequency of developing primary open-angle glaucoma (POAG) was 4.4% in the medication group and 9.5% in the observation group (hazard ratio for medication, 0.40; 95% confidence interval [CI], 0.27–0.59; P <.0001). At 13 years the cumulative proportion of participants who developed POAG was 0.22 (95% CI 0.19–0.25) in the original observation group and 0.16 (95% CI 0.13–0.19) in the original medication group (complementary log-log x2 P =.009). A 5-factor model (older age, higher IOP, thinner central corneal thickness, larger cup-to-disc ratio, and higher visual field pattern standard deviation) separated participants at high and low risk of developing POAG. Conclusions: Clinicians and patients can make evidence-based decisions about the management of ocular hypertension using the risk model and considering patient age, medical status, life expectancy, and personal preference. © 2018 Elsevier Inc.

Document Type: Article
Source: Scopus

"Association between posttraumatic stress disorder and lack of exercise, poor diet, obesity, and co-occuring smoking: A systematic review and meta-analysis" (2018) Health Psychology

Association between posttraumatic stress disorder and lack of exercise, poor diet, obesity, and co-occuring smoking: A systematic review and meta-analysis
(2018) Health Psychology, 37 (5), pp. 407-416. 

van den Berk-Clark, C.a , Secrest, S.a , Walls, J.a , Hallberg, E.a , Lustman, P.J.b c , Schneider, F.D.a d , Scherrer, J.F.a

a Department of Family and Community Medicine, Saint Louis University School of Medicine, United States
b Department of Psychiatry, Washington University in St. Louis, United States
c The Bell Street Clinic Opioid Treatment Program, Mental Health Service Line, John Cochran Hospital, St. Louis Veterans Healthcare System, St. Louis, MO, United States
d Department of Family and Community Medicine, University of Texas Southwestern, United States

Abstract
Objectives: Research has shown that posttraumatic stress disorder (PTSD) increases the risk of development of cardiometabolic disease (CMD) including cardiovascular disease and diabetes. Whether PTSD is also associated with behavioral risk factors (e.g., diet, exercise, smoking and obesity) for CMD, is less clear. Methods: PubMed, Web of Science, and Scopus databases were searched to obtain papers published between 1980-2016. Studies were reviewed for quality using the Quality of Cohort screen. Significance values, odds ratios (OR), 95% confidence intervals (CI), and tests of homogeneity of variance were calculated. Principal Findings: A total of 1,349 studies were identified from our search and 29 studies met all eligibility criteria. Individuals with PTSD were 5% less likely to have healthy diets (pooled adjusted OR = 0.95; 95% CI: 0.92, 0.98), 9% less likely to engage in physical activity (pooled adjusted OR = 0.91; 95% CI: 0.88, 0.93), 31% more likely to be obese (pooled adjusted OR = 1.31; 95% CI:1.25, 1.38), and about 22% more likely to be current smokers (pooled adjusted OR = 1.22; 95% CI: 1.19, 1.26), than individuals without PTSD. Conclusions: Evidence shows PTSD is associated with reduced healthy eating and physical activity, and increased obesity and smoking. The well-established association between PTSD and metabolic and cardiovascular disease may be partly due to poor diet, sedentary lifestyle, high prevalence of obesity, and co-occurring smoking in this population. The well-established association of PTSD with CMD is likely due in part to poor health behaviors in this patient population. © 2018 American Psychological Association.

Author Keywords
Cardiometabolic disease;  Diet;  Exercise;  PTSD;  Smoking

Document Type: Article
Source: Scopus

"Maternal mental health during the neonatal period: Relationships to the occupation of parenting" (2018) Early Human Development

Maternal mental health during the neonatal period: Relationships to the occupation of parenting
(2018) Early Human Development, 120, pp. 31-39. 

Harris, R.a , Gibbs, D.b , Mangin-Heimos, K.c d , Pineda, R.a c

a Program in Occupational Therapy, Washington University School of Medicine, St. Louis, MO, United States
b Barts Health NHS Trust, London, United Kingdom
c Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, United States
d Department of Psychological and Brain Sciences, Washington University, St. Louis, MO, United States

Abstract
Purpose: To (1) examine the extent of a range of early mental health challenges in mothers with a very preterm infant hospitalized in the NICU and mothers of full-term infants, (2) identify family social background and infant medical factors associated with higher levels of maternal psychological distress, and (3) assess the relationship between maternal psychological distress and maternal perceptions of the parenting role, parenting confidence and NICU engagement. Methods: At hospital discharge 37 mothers of very preterm infants (≤32 weeks gestation) and 47 mothers of full-term infants (≥37 weeks gestation) completed structured assessments of their psychological wellbeing and transition to parenting. Mothers of very preterm infants were also questioned about their NICU visitation and involvement in infant care. Results: Sixty-four percent (n = 54) of mothers experienced psychological distress (n = 26, 70% of preterm; n = 28, 60% of full-term). Lower infant birthweight was associated with maternal psychological distress (p =.03). Mothers of very preterm infants had significantly more psychological distress related to having a Cesarean section delivery (p =.02). Higher levels of psychological distress were associated with lower levels of parenting confidence in mothers of both very preterm and full-term infants (p <.02). Conclusion: Although parents of very preterm infants have higher rates of maternal mental health challenges, mothers of full-term infants at high social risk are also impacted. © 2018 Elsevier B.V.

Author Keywords
NICU;  Parenting;  Postnatal;  Preterm;  Psychology

Document Type: Article
Source: Scopus

"Williams–Beuren syndrome in diverse populations" (2018) American Journal of Medical Genetics

Williams–Beuren syndrome in diverse populations
(2018) American Journal of Medical Genetics, Part A, 176 (5), pp. 1128-1136. 

Kruszka, P.a , Porras, A.R.b , de Souza, D.H.c , Moresco, A.d , Huckstadt, V.d , Gill, A.D.a , Boyle, A.P.b , Hu, T.a , Addissie, Y.A.a , Mok, G.T.K.e , Tekendo-Ngongang, C.f , Fieggen, K.f , Prijoles, E.J.g , Tanpaiboon, P.h , Honey, E.i , Luk, H.-M.j , Lo, I.F.M.j , Thong, M.-K.k , Muthukumarasamy, P.k , Jones, K.L.l , Belhassan, K.a m , Ouldim, K.m , El Bouchikhi, I.m n , Bouguenouch, L.m , Shukla, A.o , Girisha, K.M.o , Sirisena, N.D.p , Dissanayake, V.H.W.p , Paththinige, C.S.p , Mishra, R.p , Kisling, M.S.h , Ferreira, C.R.h , de Herreros, M.B.q , Lee, N.-C.r , Jamuar, S.S.s , Lai, A.s , Tan, E.S.s , Ying Lim, J.s , Wen-Min, C.B.s , Gupta, N.t , Lotz-Esquivel, S.u , Badilla-Porras, R.v , Hussen, D.F.w , El Ruby, M.O.x , Ashaat, E.A.x , Patil, S.J.y , Dowsett, L.z , Eaton, A.aa , Innes, A.M.aa , Shotelersuk, V.ab , Badoe, Ë.ac , Wonkam, A.f , Obregon, M.G.d , Chung, B.H.Y.e , Trubnykova, M.ad , La Serna, J.ad , Gallardo Jugo, B.E.ad , Chávez Pastor, M.ad , Abarca Barriga, H.H.ad , Megarbane, A.ae , Kozel, B.A.af , van Haelst, M.M.ag , Stevenson, R.E.g , Summar, M.h , Adeyemo, A.A.ah , Morris, C.A.ai , Moretti-Ferreira, D.c , Linguraru, M.G.b , Muenke, M.a

a Medical Genetics Branch, National Human Genome Research Institute, The National Institutes of Health, Bethesda, MD, United States
b Sheikh Zayed Institute for Pediatric Surgical Innovation, Children’s National Health System, Washington, DC, United States
c Department of Genetics, Institute of Biosciences, Sao Paulo State University – UNESP, São Paulo, Brazil
d Servicio de Genética, Hospital de Pediatría Garrahan, Buenos Aires, Argentina
e Department of Paediatrics and Adolescent Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong
f Division of Human Genetics, University of Cape Town, Cape Town, South Africa
g Greenwood Genetic Center, Greenwood, SC, United States
h Rare Disease Institute, Children’s National Medical Center, Washington, DC, United States
i Department of Genetics, University of Pretoria, Pretoria, South Africa
j Clinical Genetic Service, Department of Health, Hong Kong Special Administrative Region, Hong Kong
k Department of Paediatrics, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
l Division of Medical Genetics and Metabolism, Children’s Hospital of The King’s Daughters, Norfolk, VA, United States
m Medical Genetics and Oncogenetics Unit, Hassan II University Hospital, Fez, Morocco
n Laboratory of Microbial Biotechnology, Faculty of Sciences and Techniques, University of Sidi Mohammed Ben Abdellah, Fez, Morocco
o Department of Medical Genetics, Kasturba Medical College, Manipal University, Manipal, India
p Human Genetics Unit, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka
q National Secretariat for the Rights of People with Disabilities (SENADIS), Fernando de la Mora, Paraguay
r Department of Pediatrics and Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan
s Genetics Service, Department of Paediatrics, KK Women’s and Children’s Hospital, Singapore, Singapore
t Division of Genetics, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India
u Research Department, Hospital San Juan de Dios (CCSS), San José, Costa Rica
v Medical Genetics and Metabolism Department, Hospital Nacional de Niños (CCSS), San José, Costa Rica
w Department of Human Cytogenetics, The National Research Centre, Cairo, Egypt
x Clinical Genetics Department, National Research Centre, Cairo, Egypt
y Mazumdar Shaw Medical Center, Narayana Health City, Bangalore, India
z Kapi’olani Medical Center for Women and Children, Honolulu, HI, United States
aa Department of Medical Genetics and Alberta Children’s Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, United States
ab Center of Excellence for Medical Genetics, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
ac School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Accra, Ghana
ad Instituto Nacional de Salud del Niño, Lima, Peru
ae Institut Jérôme Lejeune, Paris, France
af National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, United States
ag Department of Genetics, University Medical Centre, Utrecht, Utrecht, Netherlands
ah Center for Research on Genomics and Global Health, National Human Genome Research Institute, The National Institutes of Health, Bethesda, MD, United States
ai Department of Pediatrics (Genetics Division), University of Nevada School of Medicine, Las Vegas, NV, United States

Abstract
Williams–Beuren syndrome (WBS) is a common microdeletion syndrome characterized by a 1.5Mb deletion in 7q11.23. The phenotype of WBS has been well described in populations of European descent with not as much attention given to other ethnicities. In this study, individuals with WBS from diverse populations were assessed clinically and by facial analysis technology. Clinical data and images from 137 individuals with WBS were found in 19 countries with an average age of 11 years and female gender of 45%. The most common clinical phenotype elements were periorbital fullness and intellectual disability which were present in greater than 90% of our cohort. Additionally, 75% or greater of all individuals with WBS had malar flattening, long philtrum, wide mouth, and small jaw. Using facial analysis technology, we compared 286 Asian, African, Caucasian, and Latin American individuals with WBS with 286 gender and age matched controls and found that the accuracy to discriminate between WBS and controls was 0.90 when the entire cohort was evaluated concurrently. The test accuracy of the facial recognition technology increased significantly when the cohort was analyzed by specific ethnic population (P-value < 0.001 for all comparisons), with accuracies for Caucasian, African, Asian, and Latin American groups of 0.92, 0.96, 0.92, and 0.93, respectively. In summary, we present consistent clinical findings from global populations with WBS and demonstrate how facial analysis technology can support clinicians in making accurate WBS diagnoses. © 2018 Wiley Periodicals, Inc.

Author Keywords
Africa;  Asia;  diverse populations;  facial analysis technology;  Latin America;  Middle East;  syndrome;  Williams;  Williams–Beuren

Document Type: Article
Source: Scopus

"The development of temperament and character during adolescence: The processes and phases of change" (2018) Development and Psychopathology

The development of temperament and character during adolescence: The processes and phases of change
(2018) Development and Psychopathology, pp. 1-17. Article in Press. 

Zohar, A.H.a , Zwir, I.b , Wang, J.b , Cloninger, C.R.b , Anokhin, A.P.b

a Ruppin Academic Center, Israel
b Washington University School of Medicine, St. Louis

Abstract
We studied the pattern of personality development in a longitudinal population-based sample of 752 American adolescents. Personality was assessed reliably with the Junior Temperament and Character Inventory at 12, 14, and 16 years of age. The rank-order stability of Junior Temperament and Character Inventory traits from age 12 to 16 was moderate (r = .35). Hierarchical linear modeling of between-group variance due to gender and within-group variance due to age indicated that harm avoidance and persistence decreased whereas self-directedness and cooperativeness increased from age 12 to 16. Novelty seeking, reward dependence, and self-transcendence increased from age 12 to 14 and then decreased. This biphasic pattern suggests that prior to age 14 teens became more emancipated from adult authorities while identifying more with the emergent norms of their peers, and after age 14 their created identity was internalized. Girls were more self-directed and cooperative than boys and maintained this advantage from age 12 to 16. Dependability of temperament at age 16 was mainly predicted by the same traits at earlier ages. In contrast, maturity of character at age 16 was predicted by both temperament and character at earlier ages. We conclude that character develops rapidly in adolescence to self-regulate temperament in accord with personally valued goals shaped by peers. Copyright © Cambridge University Press 2018

Document Type: Article in Press
Source: Scopus

"Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression" (2018) Nature Genetics

Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression
(2018) Nature Genetics, pp. 1-14. Article in Press. 

Wray, N.R.a b , Ripke, S.c d e , Mattheisen, M.f g h i , Trzaskowski, M.a , Byrne, E.M.a , Abdellaoui, A.j , Adams, M.J.k , Agerbo, E.h l m , Air, T.M.n , Andlauer, T.M.F.o p , Bacanu, S.-A.q , Bækvad-Hansen, M.h r , Beekman, A.F.T.s , Bigdeli, T.B.q t , Binder, E.B.o u , Blackwood, D.R.H.k , Bryois, J.v , Buttenschøn, H.N.g h w , Bybjerg-Grauholm, J.h r , Cai, N.x y , Castelao, E.z , Christensen, J.H.f g h , Clarke, T.-K.k , Coleman, J.I.R.aa , Colodro-Conde, L.ab , Couvy-Duchesne, B.b ac , Craddock, N.ad , Crawford, G.E.ae af , Crowley, C.A.ag , Dashti, H.S.c ah , Davies, G.ai , Deary, I.J.ai , Degenhardt, F.aj ak , Derks, E.M.ab , Direk, N.al am , Dolan, C.V.j , Dunn, E.C.an ao ap , Eley, T.C.aa , Eriksson, N.aq , Escott-Price, V.ar , Kiadeh, F.H.F.as , Finucane, H.K.at au , Forstner, A.J.aj ak av aw , Frank, J.ax , Gaspar, H.A.aa , Gill, M.ay , Giusti-Rodríguez, P.az , Goes, F.S.ba , Gordon, S.D.bb , Grove, J.f g h bc , Hall, L.S.k bd , Hannon, E.be , Hansen, C.S.h r , Hansen, T.F.bf bg bh , Herms, S.aj ak aw , Hickie, I.B.bi , Hoffmann, P.aj ak aw , Homuth, G.bj , Horn, C.bk , Hottenga, J.-J.j , Hougaard, D.M.h r , Hu, M.bl , Hyde, C.L.bm , Ising, M.bn , Jansen, R.s , Jin, F.bo bp , Jorgenson, E.bq , Knowles, J.A.br , Kohane, I.S.bs bt bu , Kraft, J.e , Kretzschmar, W.W.bv , Krogh, J.bw , Kutalik, Z.bx by , Lane, J.M.c ah bz , Li, Y.bv , Li, Y.ag az , Lind, P.A.ab , Liu, X.bp , Lu, L.bp , MacIntyre, D.J.ca cb , MacKinnon, D.F.ba , Maier, R.M.b , Maier, W.cc , Marchini, J.cd , Mbarek, H.j , McGrath, P.ce , McGuffin, P.aa , Medland, S.E.ab , Mehta, D.b cf , Middeldorp, C.M.j cg ch , Mihailov, E.ci , Milaneschi, Y.s , Milani, L.ci , Mill, J.be , Mondimore, F.M.ba , Montgomery, G.W.a , Mostafavi, S.cj ck , Mullins, N.aa , Nauck, M.cl cm , Ng, B.ck , Nivard, M.G.j , Nyholt, D.R.cn , O’Reilly, P.F.aa , Oskarsson, H.co , Owen, M.J.cp , Painter, J.N.ab , Pedersen, C.B.h l m , Pedersen, M.G.h l m , Peterson, R.E.q cq , Pettersson, E.v , Peyrot, W.J.s , Pistis, G.z , Posthuma, D.cr cs , Purcell, S.M.ct , Quiroz, J.A.cu , Qvist, P.f g h , Rice, J.P.cv , Riley, B.P.q , Rivera, M.aa cw , Saeed Mirza, S.am , Saxena, R.c ah bz , Schoevers, R.cx , Schulte, E.C.cy cz , Shen, L.bq , Shi, J.da , Shyn, S.I.db , Sigurdsson, E.dc , Sinnamon, G.B.C.dd , Smit, J.H.s , Smith, D.J.de , Stefansson, H.df , Steinberg, S.df , Stockmeier, C.A.dg , Streit, F.ax , Strohmaier, J.ax , Tansey, K.E.dh , Teismann, H.di , Teumer, A.dj , Thompson, W.h bg dk dl , Thomson, P.A.dm , Thorgeirsson, T.E.df , Tian, C.aq , Traylor, M.dn , Treutlein, J.ax , Trubetskoy, V.e , Uitterlinden, A.G.do , Umbricht, D.dp , van der Auwera, S.dq , van Hemert, A.M.dr , Viktorin, A.v , Visscher, P.M.a b , Wang, Y.h bg dk , Webb, B.T.ds , Weinsheimer, S.M.h bg , Wellmann, J.di , Willemsen, G.j , Witt, S.H.ax , Wu, Y.a , Xi, H.S.dt , Yang, J.a b , Zhang, F.a , eQTLGenfb , 23andMefb , Arolt, V.du , Baune, B.T.n , Berger, K.di , Boomsma, D.I.j , Cichon, S.aj aw dv dw , Dannlowski, U.du , de Geus, E.C.J.j dx , DePaulo, J.R.ba , Domenici, E.dy , Domschke, K.dz , Esko, T.c ci , Grabe, H.J.dq , Hamilton, S.P.ea , Hayward, C.eb , Heath, A.C.cv , Hinds, D.A.aq , Kendler, K.S.q , Kloiber, S.bn ec ed , Lewis, G.ee , Li, Q.S.ef , Lucae, S.bn , Madden, P.F.A.cv , Magnusson, P.K.v , Martin, N.G.bb , McIntosh, A.M.k ai , Metspalu, A.ci eg , Mors, O.h eh , Mortensen, P.B.g h l m , Müller-Myhsok, B.o p ei , Nordentoft, M.h ej , Nöthen, M.M.aj ak , O’Donovan, M.C.cp , Paciga, S.A.ek , Pedersen, N.L.v , Penninx, B.W.J.H.s , Perlis, R.H.ao el , Porteous, D.J.dm , Potash, J.B.em , Preisig, M.z , Rietschel, M.ax , Schaefer, C.bq , Schulze, T.G.ax ba cz en eo , Smoller, J.W.an ao ap , Stefansson, K.df ep , Tiemeier, H.am eq er , Uher, R.es , Völzke, H.dj , Weissman, M.M.ce et , Werge, T.h bg eu , Winslow, A.R.ev ew , Lewis, C.M.aa ex , Levinson, D.F.ey , Breen, G.aa ez , Børglum, A.D.f g h , Sullivan, P.F.v az fa , the Major Depressive Disorder Working Group of the Psychiatric Genomics Consortiumfb

a Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, Australia
b Queensland Brain Institute, University of Queensland, Brisbane, QLD, Australia
c Medical and Population Genetics, Broad Institute, Cambridge, MA, United States
d Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, United States
e Department of Psychiatry and Psychotherapy, Universitätsmedizin Berlin Campus Charité Mitte, Berlin, Germany
f Department of Biomedicine, Aarhus University, Aarhus, Denmark
g iSEQ, Centre for Integrative Sequencing, Aarhus University, Aarhus, Denmark
h iPSYCH, Lundbeck Foundation Initiative for Integrative Psychiatric Research, Aarhus, Denmark
i Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
j Department of Biological Psychology and EMGO+ Institute for Health and Care Research, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
k Division of Psychiatry, University of Edinburgh, Edinburgh, United Kingdom
l Centre for Integrated Register-Based Research, Aarhus University, Aarhus, Denmark
m National Centre for Register-Based Research, Aarhus University, Aarhus, Denmark
n Discipline of Psychiatry, University of Adelaide, Adelaide, SA, Australia
o Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany
p Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
q Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, United States
r Center for Neonatal Screening, Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark
s Department of Psychiatry, Vrije Universiteit Medical Center and GGZ inGeest, Amsterdam, Netherlands
t Virginia Institute for Psychiatric and Behavior Genetics, Richmond, VA, United States
u Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, United States
v Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
w Department of Clinical Medicine, Translational Neuropsychiatry Unit, Aarhus University, Aarhus, Denmark
x Statistical Genomics and Systems Genetics, European Bioinformatics Institute (EMBL-EBI), Cambridge, United Kingdom
y Human Genetics, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
z Department of Psychiatry, University Hospital of Lausanne, Prilly, Switzerland
aa MRC Social Genetic and Developmental Psychiatry Centre, King’s College London, London, United Kingdom
ab Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia
ac Centre for Advanced Imaging, University of Queensland, Brisbane, QLD, Australia
ad Psychological Medicine, Cardiff University, Cardiff, United Kingdom
ae Center for Genomic and Computational Biology, Duke University, Durham, NC, United States
af Department of Pediatrics, Division of Medical Genetics, Duke University, Durham, NC, United States
ag Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
ah Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, United States
ai Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, United Kingdom
aj Institute of Human Genetics, University of Bonn, Bonn, Germany
ak Life & Brain Center, Department of Genomics, University of Bonn, Bonn, Germany
al Psychiatry, Dokuz Eylul University School of Medicine, Izmir, Turkey
am Epidemiology, Erasmus MC, Rotterdam, Netherlands
an Stanley Center for Psychiatric Research, Broad Institute, Cambridge, MA, United States
ao Department of Psychiatry, Massachusetts General Hospital, Boston, MA, United States
ap Psychiatric and Neurodevelopmental Genetics Unit (PNGU), Massachusetts General Hospital, Boston, MA, United States
aq Research, 23andMe, Inc., Mountain View, CA, United States
ar Neuroscience and Mental Health, Cardiff University, Cardiff, United Kingdom
as Bioinformatics, University of British Columbia, Vancouver, BC, Canada
at Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, United States
au Department of Mathematics, Massachusetts Institute of Technology, Cambridge, MA, United States
av Department of Psychiatry (UPK), University of Basel, Basel, Switzerland
aw Human Genomics Research Group, Department of Biomedicine, University of Basel, Basel, Switzerland
ax Department of Genetic Epidemiology in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
ay Department of Psychiatry, Trinity College Dublin, Dublin, Ireland
az Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
ba Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD, United States
bb Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
bc Bioinformatics Research Centre, Aarhus University, Aarhus, Denmark
bd Institute of Genetic Medicine, Newcastle University, Newcastle-upon-Tyne, United Kingdom
be University of Exeter Medical School, Exeter, United Kingdom
bf Danish Headache Centre, Department of Neurology, Rigshospitalet, Glostrup, Denmark
bg Institute of Biological Psychiatry, Mental Health Center Sct. Hans, Mental Health Services Capital Region of Denmark, Copenhagen, Denmark
bh iPSYCH, Lundbeck Foundation Initiative for Psychiatric Research, Copenhagen, Denmark
bi Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia
bj Interfaculty Institute for Genetics and Functional Genomics, Department of Functional Genomics, University Medicine and Ernst Moritz Arndt University Greifswald, Greifswald, Germany
bk Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann–La Roche, Ltd, Basel, Switzerland
bl Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, United States
bm Statistics, Pfizer Global Research and Development, Groton, CT, United States
bn Max Planck Institute of Psychiatry, Munich, Germany
bo Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, United States
bp Department of Genetics and Genome Sciences, Case Western Reserve University, Cleveland, OH, United States
bq Division of Research, Kaiser Permanente Northern California, Oakland, CA, United States
br Psychiatry and Behavioral Sciences, University of Southern California, Los Angeles, CA, United States
bs Informatics Program, Boston Children’s Hospital, Boston, MA, United States
bt Department of Medicine, Brigham and Women’s Hospital, Boston, MA, United States
bu Department of Biomedical Informatics, Harvard Medical School, Boston, MA, United States
bv Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
bw Department of Endocrinology at Herlev University Hospital, University of Copenhagen, Copenhagen, Denmark
bx Swiss Institute of Bioinformatics, Lausanne, Switzerland
by Institute of Social and Preventive Medicine (IUMSP), University Hospital of Lausanne, Lausanne, Switzerland
bz Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA, United States
ca Mental Health, Glasgow, United Kingdom
cb Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
cc Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany
cd Statistics, University of Oxford, Oxford, United Kingdom
ce Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, United States
cf School of Psychology and Counseling, Queensland University of Technology, Brisbane, QLD, Australia
cg Child and Youth Mental Health Service, Children’s Health Queensland Hospital and Health Service, South Brisbane, QLD, Australia
ch Child Health Research Centre, University of Queensland, Brisbane, QLD, Australia
ci Estonian Genome Center, University of Tartu, Tartu, Estonia
cj Medical Genetics, University of British Columbia, Vancouver, BC, Canada
ck Statistics, University of British Columbia, Vancouver, BC, Canada
cl DZHK (German Centre for Cardiovascular Research), partner site Greifswald, University Medicine, University Medicine Greifswald, Greifswald, Germany
cm Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany
cn Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD, Australia
co Humus, Reykjavik, Iceland
cp MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, United Kingdom
cq Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, United States
cr Complex Trait Genetics, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
cs Clinical Genetics, Vrije Universiteit Medical Center, Amsterdam, Netherlands
ct Department of Psychiatry, Brigham and Women’s Hospital, Boston, MA, United States
cu Solid Biosciences, Boston, MA, United States
cv Department of Psychiatry, Washington University in St. Louis School of Medicine, St. Louis, MO, United States
cw Department of Biochemistry and Molecular Biology II, Institute of Neurosciences, Center for Biomedical Research, University of Granada, Granada, Spain
cx Department of Psychiatry, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
cy Department of Psychiatry and Psychotherapy, Medical Center of the University of Munich, Campus Innenstadt, Munich, Germany
cz Institute of Psychiatric Phenomics and Genomics (IPPG), Medical Center of the University of Munich, Campus Innenstadt, Munich, Germany
da Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, United States
db Behavioral Health Services, Kaiser Permanente Washington, Seattle, WA, United States
dc Faculty of Medicine, Department of Psychiatry, University of Iceland, Reykjavik, Iceland
dd School of Medicine and Dentistry, James Cook University, Townsville, QLD, Australia
de Institute of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom
df deCODE Genetics/Amgen, Inc., Reykjavik, Iceland
dg Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, United States
dh College of Biomedical and Life Sciences, Cardiff University, Cardiff, United Kingdom
di Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany
dj Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany
dk KG Jebsen Centre for Psychosis Research, Norway Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
dl Department of Psychiatry, University of California, San Diego, La Jolla, CA, United States
dm Medical Genetics Section, CGEM, IGMM, University of Edinburgh, Edinburgh, United Kingdom
dn Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom
do Internal Medicine, Erasmus MC, Rotterdam, Netherlands
dp Roche Pharmaceutical Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases Discovery and Translational Medicine Area, Roche Innovation Center Basel, F. Hoffmann–La Roche, Ltd, Basel, Switzerland
dq Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany
dr Department of Psychiatry, Leiden University Medical Center, Leiden, Netherlands
ds Virginia Institute of Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, United States
dt Computational Sciences Center of Emphasis, Pfizer Global Research and Development, Cambridge, MA, United States
du Department of Psychiatry, University of Münster, Munster, Germany
dv Institute of Neuroscience and Medicine (INM-1), Research Center Juelich, Juelich, Germany
dw Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
dx Amsterdam Public Health Institute, Vrije Universiteit Medical Center, Amsterdam, Netherlands
dy Centre for Integrative Biology, Università degli Studi di Trento, Trento, Italy
dz Department of Psychiatry and Psychotherapy, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
ea Psychiatry, Kaiser Permanente Northern California, San Francisco, CA, United States
eb MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, United Kingdom
ec Centre for Addiction and Mental Health, Toronto, Ontario, Canada
ed Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
ee Division of Psychiatry, University College London, London, United Kingdom
ef Neuroscience Therapeutic Area, Janssen Research and Development, LLC, Titusville, NJ, United States
eg Institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia
eh Psychosis Research Unit, Aarhus University Hospital, Risskov, Aarhus, Denmark
ei Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom
ej Mental Health Center Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark
ek Human Genetics and Computational Biomedicine, Pfizer Global Research and Development, Groton, CT, United States
el Psychiatry, Harvard Medical School, Boston, MA, United States
em Psychiatry, University of Iowa, Iowa City, IA, United States
en Human Genetics Branch, NIMH Division of Intramural Research Programs, Bethesda, MD, United States
eo Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany
ep Faculty of Medicine, University of Iceland, Reykjavik, Iceland
eq Child and Adolescent Psychiatry, Erasmus MC, Rotterdam, Netherlands
er Psychiatry, Erasmus MC, Rotterdam, Netherlands
es Psychiatry, Dalhousie University, Halifax, NS, Canada
et Division of Epidemiology, New York State Psychiatric Institute, New York, NY, United States
eu Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
ev Human Genetics and Computational Biomedicine, Pfizer Global Research and Development, Cambridge, MA, United States
ew Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
ex Department of Medical and Molecular Genetics, King’s College London, London, United Kingdom
ey Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, United States
ez NIHR BRC for Mental Health, King’s College London, London, United Kingdom
fa Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

Abstract
Major depressive disorder (MDD) is a common illness accompanied by considerable morbidity, mortality, costs, and heightened risk of suicide. We conducted a genome-wide association meta-analysis based in 135,458 cases and 344,901 controls and identified 44 independent and significant loci. The genetic findings were associated with clinical features of major depression and implicated brain regions exhibiting anatomical differences in cases. Targets of antidepressant medications and genes involved in gene splicing were enriched for smaller association signal. We found important relationships of genetic risk for major depression with educational attainment, body mass, and schizophrenia: lower educational attainment and higher body mass were putatively causal, whereas major depression and schizophrenia reflected a partly shared biological etiology. All humans carry lesser or greater numbers of genetic risk factors for major depression. These findings help refine the basis of major depression and imply that a continuous measure of risk underlies the clinical phenotype. © 2018 The Author(s)

Document Type: Article in Press
Source: Scopus

"Extended Twin Study of Alcohol Use in Virginia and Australia" (2018) Twin Research and Human Genetics

Extended Twin Study of Alcohol Use in Virginia and Australia
(2018) Twin Research and Human Genetics, pp. 1-16. Article in Press. 

Verhulst, B.a , Neale, M.C.b , Eaves, L.J.b , Medland, S.E.c , Heath, A.C.d , Martin, N.G.c , Maes, H.H.b

a Department of Psychology, Michigan State University, East Lansing, MI, USA
b Department of Psychiatry and Department of Human Genetics, Virginia Commonwealth University, Richmond, VA, USA
c Department of Genetic Epidemiology, QIMR Berghofer Medical Research Institute, Royal Brisbane Hospital, Brisbane, Australia
d Department of Psychiatry Washington University, St. Louis, MO, USA

Abstract
Drinking alcohol is a normal behavior in many societies, and prior studies have demonstrated it has both genetic and environmental sources of variation. Using two very large samples of twins and their first-degree relatives (Australia ≈ 20,000 individuals from 8,019 families; Virginia ≈ 23,000 from 6,042 families), we examine whether there are differences: (1) in the genetic and environmental factors that influence four interrelated drinking behaviors (quantity, frequency, age of initiation, and number of drinks in the last week), (2) between the twin-only design and the extended twin design, and (3) the Australian and Virginia samples. We find that while drinking behaviors are interrelated, there are substantial differences in the genetic and environmental architectures across phenotypes. Specifically, drinking quantity, frequency, and number of drinks in the past week have large broad genetic variance components, and smaller but significant environmental variance components, while age of onset is driven exclusively by environmental factors. Further, the twin-only design and the extended twin design come to similar conclusions regarding broad-sense heritability and environmental transmission, but the extended twin models provide a more nuanced perspective. Finally, we find a high level of similarity between the Australian and Virginian samples, especially for the genetic factors. The observed differences, when present, tend to be at the environmental level. Implications for the extended twin model and future directions are discussed. Copyright © The Author(s) 2018

Author Keywords
age of drinking onset;  broad-sense heritability;  broad-sense heritability;  drinking frequency;  drinking quantity;  extended twin model;  number of drinks in the last week

Document Type: Article in Press
Source: Scopus

"Agreement between clinician-rated versus patient-reported outcomes in Huntington disease" (2018) Journal of Neurology

Agreement between clinician-rated versus patient-reported outcomes in Huntington disease
(2018) Journal of Neurology, pp. 1-11. Article in Press. 

Carlozzi, N.E.a , Boileau, N.R.a , Perlmutter, J.S.b , Chou, K.L.c , Stout, J.C.d , Paulsen, J.S.e f g , McCormack, M.K.h i , Cella, D.j , Nance, M.A.k l , Lai, J.-S.j , Dayalu, P.c

a Department of Physical Medicine and Rehabilitation, University of Michigan, North Campus Research Complex, 2800 Plymouth Road, Building NCRC B14, Room G216, Ann Arbor, MI, United States
b Neurology, Radiology, Neuroscience, Physical Therapy and Occupational Therapy, Washington University in St. Louis, St. Louis, United States
c Department of Neurology, University of Michigan, Ann Arbor, United States
d School of Psychological Sciences, Monash University, Clayton, VIC, Australia
e Department of Psychiatry, Carver College of Medicine, The University of Iowa, Iowa City, IA, United States
f Department of Neurology, Carver College of Medicine, The University of Iowa, Iowa City, IA, United States
g Department of Psychological and Brain Sciences, The University of Iowa, Iowa City, IA, United States
h Department of Psychiatry, Rutgers-RWJMS, Piscataway, NJ, United States
i Department of Pathology, Rowan-SOM, Stratford, NJ, United States
j Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Evanston, IL, United States
k Struthers Parkinson’s Center, Golden Valley, MN, United States
l Hennepin County Medical Center, Minneapolis, MN, United States

Abstract
Background: Clinician-rated measures of functioning are often used as primary endpoints in clinical trials and other behavioral research in Huntington disease. As study costs for clinician-rated assessments are not always feasible, there is a question of whether patient self-report of commonly used clinician-rated measures may serve as acceptable alternatives in low risk behavioral trials. Aim: The purpose of this paper was to determine the level of agreement between self-report and clinician-ratings of commonly used functional assessment measures in Huntington disease. Design: 486 participants with premanifest or manifest Huntington disease were examined. Total Functional Capacity, Functional Assessment, and Independence Scale assessments from the Unified Huntington Disease Rating scale were completed by clinicians; a self-report version was also completed by individuals with Huntington disease. Cronbach’s α was used to examine internal consistency, one-way analysis of variance was used to examine group differences, and paired t tests, kappa agreement coefficients, and intra-class correlations were calculated to determine agreement between raters. Results: Internal consistency for self-reported ratings of functional capacity and ability were good. There were significant differences between those with premanifest, early-, and late-stage disease; those with later-stage disease reported less ability and independence than the other clinical groups. Although self-report ratings were not a perfect match with associated clinician-rated measures, differences were small. Cutoffs for achieving specified levels of agreement are provided. Conclusions: Depending on the acceptable margin of error in a study, self-reported administration of these functional assessments may be appropriate when clinician-related assessments are not feasible. © 2018 Springer-Verlag GmbH Germany, part of Springer Nature

Author Keywords
Clinician-ratings;  Functioning;  Huntington disease;  Self-report ratings

Document Type: Article in Press
Source: Scopus

"A novel 4-rod technique offers potential to reduce rod breakage and pseudarthrosis in pedicle subtraction osteotomies for adult spinal deformity correction" (2018) Operative Neurosurgery

A novel 4-rod technique offers potential to reduce rod breakage and pseudarthrosis in pedicle subtraction osteotomies for adult spinal deformity correction
(2018) Operative Neurosurgery, 14 (4), pp. 449-456. 

Gupta, S.a , Eksi, M.S.b , Ames, C.P.c , Deviren, V.b , Durbin-Johnson, B.a , Smith, J.S.d , Gupta, M.C.e

a Department of Orthopaedic Surgery, University of California, Davis, Sacramento, CA, United States
b Department of Orthopaedic Surgery, University of California, San Francisco, San Francisco, CA, United States
c Department of Neurosurgery, University of California, San Francisco, San Francisco, CA, United States
d Department of Neurosurgery, University of Virginia, Charlottesville, VA, United States
e Department of Orthopaedic Surgery, Washington University, St Louis, MO, United States

Abstract
BACKGROUND: Pedicle subtraction osteotomy (PSO) can be used to treat rigid sagittal plane deformities. Nonunions and rod breakages are known complications of PSO. OBJECTIVE: To assess outcomes of 2methods of posterior instrumentation for PSO, traditional 2 rods vs a novel 4-rod technique inwhich 2 additional rods span only the osteotomy level. METHODS: This study was a retrospective, radiographic review of consecutive PSOs performed at 2 centers. The primary difference in technique between the centers was the use of 4 rods including 2 independent rods attached only to the vertebral levels immediately adjacent to thePSO(group 1, n=29 patients) vs the traditional 2-rod technique (group 2, n = 20 patients). RESULTS: Demographics and preoperative to postoperative radiographic measurements were similar between the study groups, including the PSO wedge resection angle (P=.56). The rod breakage rate was 25% with 2 rods and 0%with 4 rods (P=.008), and the pseudarthrosis rate with 2 rods was 25% and with 4 rods was 3.4% (P = .035). The patient with pseudarthrosis fromgroup 1 had an infection and developed pseudarthrosis only after instrumentation removal. Rates of other complications did not differ significantly between the study groups. CONCLUSION: This study provides a comparison between 2 techniques for rod placement across a PSO and suggests that the described novel 4-rod technique may help to reduce the rates of pseudarthrosis and rod failure. It will be important to confirm these findings in a prospectively designed study with multiple institutions in order to better control for potentially confounding factors. © 2017 by the Congress of Neurological Surgeons.

Author Keywords
4-rod technique;  Complications;  Deformity;  Fusion;  Pedicle subtraction osteotomy;  Pseudarthrosis

Document Type: Article
Source: Scopus

"Population-based approaches to treatment and readmission after spinal cord injury" (2018) Journal of Neurosurgical Sciences

Population-based approaches to treatment and readmission after spinal cord injury
(2018) Journal of Neurosurgical Sciences, 62 (2), pp. 107-115. 

Yarbrough, C.K.a , Bommarito, K.M.b c , Gamble, P.G.d , Hawasli, A.H.a , Dorward, I.G.a , Olsen, M.A.b c , Ray, W.Z.a

a Department of Neurosurgery, Washington University School of Medicine, 660 S. Euclid Avenue, Campus Box 8057, St. Louis, MO, United States
b Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States
c Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO, United States
d Washington University School of Medicine, St. Louis, MO, United States

Abstract
BACKGROUND: Recent studies in surgical and non-surgical specialties have suggested that patients admitted on the weekend may have worse outcomes. In particular, patients with stroke and acute cardiovascular events have shown worse outcomes with weekend treatment. It is unclear whether this extends to patients with spinal cord injury (SCI). This study was designed to evaluate factors for readmission after index hospitalization for spinal cord injury. METHODS: This cohort was constructed from the State Inpatient Databases of California, New York, and Florida. For this study 14,396 patients with SCI were identified. The primary outcome measure evaluated was 30-day readmission. Secondary measures include in-hospital complications. Univariate and multivariate analysis were utilized to evaluate covariates. c2, Fisher’s exact, and linear, logistic, and modified Poisson regression methods were utilized for statistical analysis. Propensity score methods were used with matched pairs analysis performed by the McNemar’s Test. RESULTS: Weekend admission was not associated with increased 30-day readmission rates in multivariate analysis. Race and discharge to a facility (RR 1.60 [1.43-1.79]) or home with home care (RR 1.23 [1.07-1.42]), were statistically significant risk factors for readmission. Payor status did not affect rates of readmission. In propensity score matched pairs analysis, weekend admission was not associated with increased odds of 30-day readmission (OR 1.04 [0.89-1.21]). Patients admitted to high volume centers had significantly lower risk of readmission when compared with patients admitted to low volume centers. CONCLUSIONS: Our results suggest that the weekend effect, described previously in other patient populations, may not play as important a role in patients with SCI. © 2016 EDIZIO NI MINERVA MEDICA.

Author Keywords
Continental population groups;  Healthcare disparities;  Insurance;  Spinal cord injuries;  Surgery;  Wounds and injuries

Document Type: Article
Source: Scopus

"A neurosteroid analogue with T-type calcium channel blocking properties is an effective hypnotic, but is not harmful to neonatal rat brain" (2018) British Journal of Anaesthesia

A neurosteroid analogue with T-type calcium channel blocking properties is an effective hypnotic, but is not harmful to neonatal rat brain
(2018) British Journal of Anaesthesia, 120 (4), pp. 768-778. Cited 1 time.

Atluri, N.a , Joksimovic, S.M.a , Oklopcic, A.f , Milanovic, D.e , Klawitter, J.a , Eggan, P.a , Krishnan, K.c , Covey, D.F.c d , Todorovic, S.M.a b , Jevtovic-Todorovic, V.a

a Department of Anaesthesiology, University of Colorado, School of Medicine, Anschutz Medical Campus, Aurora, CO, United States
b Neuroscience Graduate Program, University of Colorado, School of Medicine, Anschutz Medical Campus, Aurora, CO, United States
c Department of Developmental Biology, Washington University School of Medicine, Saint Louis, MO, United States
d Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine, Saint Louis, MO, United States
e Institute for Biological Research, Department of Neurobiology, University of Belgrade, Belgrade, Serbia
f School of Nursing, University of Virginia, Charlottesville, VA, United States

Abstract
Background: More than 4 million children are exposed annually to sedatives and general anaesthetics (GAs) in the USA alone. Recent data suggest that common GAs can be detrimental to brain development causing neurodegeneration and long-term cognitive impairments. Challenged by a recent US Food and Drug Administration (FDA) warning about potentially neurotoxic effects of GAs in children, there is an urgent need to develop safer GAs. Methods: Postnatal Day 7 (P7) rat pups of both sexes were exposed to six (repeated every 2 h) injections of equipotent hypnotic doses of ketamine or the neuroactive steroid (3β,5β,17β)-3-hydroxyandrostane-17-carbonitrile (3β-OH) for 12 h. Loss of righting reflex was used to assess hypnotic properties and therapeutic index; quantitative caspase-3 immunohistochemistry was used to assess developmental neuroapoptosis; patch-clamp recordings in acute brain slices were used to assess the effects of 3β-OH on neuronal excitability and synaptic transmission. Cognitive abilities of rats exposed to ketamine, 3β-OH, or vehicle at P7 were assessed in young adulthood using the radial arm maze. Results: The neuroactive steroid 3β-OH has a therapeutic index similar to ketamine, a commonly used clinical GA. We report that 3β-OH is safe and, unlike ketamine, does not cause neuroapoptosis or impair cognitive development when administered to P7 rat pups. Interestingly, 3β-OH blocks T-type calcium channels and presynaptically dampens synaptic transmission at hypnotically-relevant brain concentrations, but it lacks a direct effect on γ-aminobutyric acid A or glutamate-gated ion channels. Conclusions: The neurosteroid 3β-OH is a relatively safe hypnotic that warrants further consideration for paediatric anaesthesia. © 2018 British Journal of Anaesthesia

Author Keywords
calcium channels;  developmental neurotoxicity;  neurosteroid

Document Type: Article
Source: Scopus

"Athymic mice reveal a requirement for T-cell-microglia interactions in establishing a microenvironment supportive of Nf1 low-grade glioma growth" (2018) Genes and Development

Athymic mice reveal a requirement for T-cell-microglia interactions in establishing a microenvironment supportive of Nf1 low-grade glioma growth
(2018) Genes and Development, 32 (7-8), pp. 491-496. 

Pan, Y.a , Xiong, M.a b , Chen, R.a , Ma, Y.a , Corman, C.a , Maricos, M.c , Kindler, U.c , Semtner, M.c , Chen, Y.-H.a d , Dahiya, S.e , Gutmann, D.H.a

a Department of Neurology, Washington University School of Medicine, St. Louis, MO, United States
b Reproductive Medicine Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
c Cellular Neuroscience, Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC, Berlin, Germany
d Genome Engineering and iPSC Center (GEIC, Washington University School of Medicine, St. Louis, MO, United States
e Division of Neuropathology, Washington University School of Medicine, St. Louis, MO, United States

Abstract
Pediatric low-grade gliomas (LGGs) frequently do not engraft in immunocompromised mice, limiting their use as an experimental platform. In contrast, murine Neurofibromatosis- 1 (Nf1) optic LGG stem cells (o-GSCs) form glioma-like lesions in wild-type, but not athymic, mice following transplantation. Here, we show that the inability of athymic mice to support o-GSC engraftment results from impaired microglia/macrophage function, including reduced expression of Ccr2 and Ccl5, both of which are required for o-GSC engraftment and Nf1 optic glioma growth. Impaired Ccr2 and Ccl5 expression in athymic microglia/macrophages was restored by T-cell exposure, establishing T-cell-microglia/macrophage interactions as critical stromal determinants that support NF1 LGG growth. © 2018 Pan et al.

Author Keywords
Chemokines;  Monocyte;  Stroma;  Tumor microenvironment

Document Type: Article
Source: Scopus

"Mode of anaesthesia for Caesarean delivery and maternal morbidity: can we overcome confounding by indication?" (2018) British Journal of Anaesthesia

Mode of anaesthesia for Caesarean delivery and maternal morbidity: can we overcome confounding by indication?
(2018) British Journal of Anaesthesia, 120 (4), pp. 621-623. 

Butwick, A.J.a , Palanisamy, A.b

a Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University School of Medicine, Stanford, CA, United States
b Department of Anesthesiology, Washington University School of Medicine, St Louis, MO, United States

Document Type: Editorial
Source: Scopus

"Schizotypal traits and verbal creativity (Szkizotip személyiségvonások és a nyelvi kreativitás összefüggéseinek vizsgálata)" (2018) Ideggyogyaszati Szemle

Schizotypal traits and verbal creativity [Szkizotip személyiségvonások és a nyelvi kreativitás összefüggéseinek vizsgálata]
(2018) Ideggyogyaszati Szemle, 71 (3-4), pp. 113-125. 

Fejes, N.É.a , Rózsa, S.b , Must, A.c

a Department of Psychiatry, School of Medicine, Washington University, Sík Sándor U.2.1/6, St. Louis, MO, United States
b Szegedi Tudományegyetem, Pszichológiai Intézet, Szeged, Hungary
c Szegedi Tudományegyetem, Pszichológiai Intezet, Kognitfv és Neuropszichológia Tanszék, Szeged, Hungary

Abstract
Introduction – The relationship of schizophrenia and its milder, subclinical forms, with creativity has been in the centre of theoretical interest for decades, however, the systematic research of the topic only prevailed more recently. Purpose – Here we aimed to examine the connection between different schizotypal and non-schizotypal personality traits and verbal creativity in a nonclinical sample. We also investigated the correspondence of two schizotypy inventories, the Oxford-Liverpool Inventory of Feelings and Experiences and a special character configuration of the Temperament and Character Inventory associated with schizotypy. Method – 57 healthy adults (14/43 m/f, mean age 21.51 ±1.43 years) – took part in the experiment. All participants received a detailed information sheet and gave informed consent prior to participation. Participants completed the Oxford-Liverpool Inventory and the Temperament and Character Inventory to measure both schizotypal and non-schizotypal personality traits. Torrance Test of Creative Thinking was used to measure verbal creativity. Associations between reported measures were examined with correlational and regression analyses. Results and conclusion – Out of the specific Temperament and Character configuration associated with schizotypy (low self-directedness, cooperativeness and high self- transcendence), we only found low self-directedness to be correlated significantly with Oxford-Liverpool schizotypy rates (Self- directedness-schizotypy: r=-.730, pc.01). There was no significant connection between schizotypal traits and verbal creativity. In our sample, the Self-directedness and Reward- dependence character and temperament subscales predicted significantly the verbal creativity level (Self-directedness: P=.330, p=.015; Reward – dependence: p=-.260; p=.049). Based on our results, besides schizotypal traits, other personality measures might be considered in relation to verbal creativity, providing further details to the empirical investigation of creativity. We found low self-directedness to be correlated with Oxford-Liverpool schizotypy rates, however, the sample size was not large enough to test the concurrent validity of the two inventories. Future studies might consider to extend the study sample, preferably to both clinical and non-clinical populations. © 2018 Ifjusagi Lap-es Konyvkiado Vallalat. All rights reserved.

Author Keywords
Creativity;  Personality inventories;  Schizotypal traits;  Schizotypy

Document Type: Article
Source: Scopus

"Reconceptualising stroke research to inform the question of anaesthetic neurotoxicity" (2018) British Journal of Anaesthesia

Reconceptualising stroke research to inform the question of anaesthetic neurotoxicity
(2018) British Journal of Anaesthesia, 120 (3), pp. 430-435. 

Vlisides, P.E.a , Avidan, M.S.b , Mashour, G.A.a c d

a Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, MI, United States
b Department of Anesthesiology, Washington University School of Medicine in St. Louis, St. Louis, MO, United States
c Center for Consciousness Science, University of Michigan Medical School, Ann Arbor, MI, United States
d Neuroscience Graduate Program, University of Michigan Medical School, Ann Arbor, MI, United States

Document Type: Editorial
Source: Scopus

"Association of depression with mortality in older adults undergoing transcatheter or surgical aortic valve replacement" (2018) JAMA Cardiology

Association of depression with mortality in older adults undergoing transcatheter or surgical aortic valve replacement
(2018) JAMA Cardiology, 3 (3), pp. 191-197. Cited 1 time.

Drudi, L.M.a b c , Ades, M.c , Turkdogan, S.c , Huynh, C.c , Lauck, S.d , Webb, J.G.d , Piazza, N.e , Martucci, G.e , Langlois, Y.f , Perrault, L.P.g , Asgar, A.W.h , Labinaz, M.i , Lamy, A.j , Noiseux, N.k , Peterson, M.D.l , Arora, R.C.m , Lindman, B.R.n , Bendayan, M.a o , Mancini, R.a , Trnkus, A.a , Kim, D.H.p , Popma, J.J.q , Afilalo, J.a c o r

a Centre for Clinical Epidemiology, Jewish General Hospital, 3755 Cote Ste Catherine Rd, Room E-222, Montreal, QC, Canada
b Division of Vascular Surgery, McGill University, Montreal, QC, Canada
c Faculty of Medicine, McGill University, Montreal, QC, Canada
d Centre for Heart Valve Innovation, University of British Columbia, St Paul’s Hospital, Vancouver, BC, Canada
e Division of Cardiology, McGill University Health Centre, Montreal, QC, Canada
f Division of Cardiac Surgery, McGill University, Jewish General Hospital, Montreal, QC, Canada
g Division of Cardiac Surgery, Institut de Cardiologie de Montréal, Université de Montréal, Montreal, QC, Canada
h Division of Cardiology, Institut de Cardiologie de Montréal, Université de Montréal, Montreal, QC, Canada
i Division of Cardiology, University of Ottawa Heart Institute, Ottawa, ON, Canada
j Population Health Research Institute, Division of Cardiac Surgery, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada
k Division of Cardiac Surgery, Centre de Recherche Du Centre Hospitalier de L’Université de Montréal, Montreal, QC, Canada
l Division of Cardiac Surgery, University of Toronto, St Michael’s Hospital, Toronto, ON, Canada
m Division of Cardiac Surgery, University of Manitoba, St Boniface Hospital, Winnipeg, MB, Canada
n Division of Cardiology, Washington University School of Medicine, St Louis, MO, United States
o Division of Experimental Medicine, McGill University, Montreal, QC, Canada
p Division of Gerontology, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA, United States
q Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA, United States
r Division of Cardiology, McGill University, Jewish General Hospital, Montreal, QC, Canada

Abstract
IMPORTANCE Depression is increasingly recognized as a risk factor for adverse outcomes in cardiovascular disease. However, little is known about depression in older adults undergoing transcatheter (TAVR) or surgical (SAVR) aortic valve replacement. OBJECTIVE To determine the prevalence of depression and its association with all-cause mortality in older adults undergoing TAVR or SAVR. DESIGN, SETTING, AND PARTICIPANTS This preplanned analysis of the Frailty Aortic Valve Replacement (FRAILTY-AVR) prospective cohort study included 14 centers in 3 countries from November 15, 2011, through April 7, 2016. Individuals 70 years or older who underwent TAVR or SAVR were enrolled. Depressive symptoms were evaluated using the Geriatric Depression Scale Short Form at baseline and follow-up. MAIN OUTCOMES AND MEASURES All-cause mortality at 1 and 12 months after TAVR or SAVR. Logistic regression was used to determine the association of depression with mortality after adjusting for confounders such as frailty and cognitive impairment. RESULTS Among 1035 older adults (427 men [41.3%] and 608 women [58.7%]) with a mean (SD) age of 81.4 (6.1) years, 326 (31.5%) had a positive result of screening for depression, whereas only 89 (8.6%) had depression documented in their clinical record. After adjusting for clinical and geriatric confounders, baseline depression was found to be associated with mortality at 1 month (odds ratio [OR], 2.20; 95%CI, 1.18-4.10) and at 12 months (OR, 1.532; 95%CI, 1.03-2.24). Persistent depression, defined as baseline depression that was still present 6 months after the procedure, was associated with a 3-fold increase in mortality at 12 months (OR, 2.98; 95%CI, 1.08-8.20). CONCLUSIONS AND RELEVANCE One in 3 older adults undergoing TAVR or SAVR had depressive symptoms at baseline and a higher risk of short-term and midterm mortality. Patients with persistent depressive symptoms at follow-up had the highest risk of mortality. © 2018 American Medical Association. All Rights Reserved.

Document Type: Article
Source: Scopus

"Cryptococcal meningitis in AIDS" (2018) Handbook of Clinical Neurology

Cryptococcal meningitis in AIDS
(2018) Handbook of Clinical Neurology, 152, pp. 139-150. 

Spec, A., Powderly, W.G.

Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States

Abstract
Cryptococcal meningitis remains a significant cause of morbidity and mortality amongst patients living with human immunodeficiency virus (HIV). The prevalence in the developed world has decreased as HIV is being diagnosed earlier, but is still significant, and the prevalence in resource-limited settings is exceedingly high. The presenting symptoms usually include a headache, fever, and, less often, cranial nerve abnormalities. Space-occupying lesions do occur, but are rare. Once diagnosed, patients should be treated with a combination of amphotericin and flucytosine, with step-down therapy to fluconazole for a minimum of a year, or until the CD4 count is above 100 cells/μL, whichever is longer. In the acute phase of treatment increased opening pressure is common, which should be managed aggressively with frequent lumbar punctures, or through neurosurgical interventions (lumbar drains, ventriculoperitoneal shunts) if those fail. Antiretrovirals should be delayed at least 2 weeks, but maybe as many as 10 weeks, after initiation of antifungal therapy in order to prevent clinical or subclinical immune reconstitution inflammatory syndrome (IRIS), which may lead to increased mortality. However, if IRIS does develop, there is no role for antiretroviral interruption, and the condition should be managed supportively by use of anti-inflammatories and aggressive management of elevated opening pressure, if present. Steroids should be administered for specific indications only (IRIS or cryptococcoma with cerebral edema and risk of herniation) as routine use of steroids increases mortality in cryptococcal meningitis. © 2018 Elsevier B.V.

Author Keywords
Africa;  amphotericin;  cryptococcal meningitis;  cryptococcus;  fluconazole;  flucytosine;  lymphocytic meningitis

Document Type: Book Chapter
Source: Scopus

"Preclinical MRI: Studies of the irradiated brain" (2018) Journal of Magnetic Resonance

Preclinical MRI: Studies of the irradiated brain
(2018) Journal of Magnetic Resonance, . Article in Press. 

Garbow, J.R.a b , Tsien, C.I.c , Beeman, S.C.a

a Department of Radiology, Washington University, Saint Louis, MO, United States
b The Alvin J. Siteman Cancer Center, Washington University, Saint Louis, MO, United States
c Department of Radiation Oncology, Washington University, Saint Louis, MO, United States

Abstract
Radiation therapy (RT) plays a central role in the treatment of primary brain tumors. However, despite recent advances in RT treatment, local recurrences following therapy remain common. Radiation necrosis (RN) is a severe, late complication of radiation therapy in the brain. RN is a serious clinical problem often associated with devastating neurologic complications. Therapeutic strategies, including neuroprotectants, have been described, but have not been widely translated in routine clinical use. We have developed a mouse model that recapitulates all of the major pathologic features of late-onset RN for the purposes of characterizing the basic pathogenesis of RN, identifying non-invasive (imaging) biomarkers of RN that might allow for the radiologic discernment of tumor and RN, systematic testing of tumor and RN therapeutics, and exploring the complex interplay between RN pathogenesis and tumor recurrence. Herein, we describe the fundamental clinical challenges associated with RN and the progress made towards addressing these challenges by combining our novel mouse model of late-onset RN and magnetic resonance imaging (MRI). MRI techniques discussed include conventional T1- and T2-weighted imaging, diffusion-weighted imaging, magnetization transfer, and measures of tissue oxygenation. Studies of RN mitigation and neuroprotection are described, including the use of anti-VEGF antibodies, and inhibitors of GSK-3β, HIF-1α, and CXCR4. We conclude with some future perspectives on the irradiated brain and the study and treatment of recurrent tumor growing in an irradiated tumor microenvironment. © 2018 Elsevier Inc.

Author Keywords
Magnetic resonance imaging;  Radiated brain;  Radiation necrosis

Document Type: Article in Press
Source: Scopus

"Testing Encourages Transfer Between Factual and Application Questions in an Online Learning Environment" (2018) Journal of Applied Research in Memory and Cognition

Testing Encourages Transfer Between Factual and Application Questions in an Online Learning Environment
(2018) Journal of Applied Research in Memory and Cognition, . Article in Press. 

Thomas, R.C.a , Weywadt, C.R.b , Anderson, J.L.b c , Martinez-Papponi, B.b , McDaniel, M.A.d

a Hendrix College, United States
b University of New Mexico, United States
c Harvard University, United States
d Washington University in St Louis, United States

Abstract
Quizzing improves retention compared to additional study opportunities, a phenomenon known as test-enhanced learning. Two experiments investigated whether the type of question at quiz improves retention for factual and applied course material on exams in an online college course. Students were given quizzes with either factual questions or questions designed to encourage application of a particular concept. As expected, quizzing with feedback improved exam performance compared to material that had not been quizzed. Further, the benefits of quizzing transferred to different question types. Performance on application exam questions improved if students were quizzed with factual questions. Likewise, performance on factual exam questions improved if students were quizzed with application questions. These results replicate the finding that quizzing benefits retention in an online learning environment and, more importantly, that the benefits of quizzing transfer to exam questions that differ in type from the quiz question. © 2018 Society for Applied Research in Memory and Cognition

Author Keywords
Memory;  Retrieval;  Test-enhanced learning;  Testing effect;  Transfer

Document Type: Article in Press
Source: Scopus

"Chalcones and Five-Membered Heterocyclic Isosteres Bind to Alpha Synuclein Fibrils in Vitro" (2018) ACS Omega

Chalcones and Five-Membered Heterocyclic Isosteres Bind to Alpha Synuclein Fibrils in Vitro
(2018) ACS Omega, 3 (4), pp. 4486-4493. 

Hsieh, C.-J.a , Xu, K.a , Lee, I.a , Graham, T.J.A.a e , Tu, Z.b , Dhavale, D.c , Kotzbauer, P.c , Mach, R.H.a d

a Department of Radiology, University of Pennsylvania, School of Medicine, Philadelphia, PA, United States
b Mallinckrodt Institute of Radiology, Washington University, School of Medicine, St. Louis, MO, United States
c Department of Neurology, Washington University, School of Medicine, St. Louis, MO, United States
d University of Pennsylvania, Chemistry Building, 231 S. 34th St, Philadelphia, PA, United States
e Translational Biomarkers, Merck Research Laboratories, West Point, PA, United States

Abstract
A series of chalcone and heterocyclic isosteres, in which the enone moiety was replaced with an isoxazole and pyrazole ring system, was synthesized and their affinities for alpha synuclein (Asyn), amyloid beta (Aβ), and tau fibrils were measured in vitro. The compounds were found to have a modest affinity and selectivity for Asyn versus Aβ fibrils and low affinity for tau fibrils. Insertion of a double bond to increase the extendable surface area resulted in an increase in affinity and improvement in selectivity for Asyn versus Aβ and tau fibrils. The results of this study indicate that compound 11 is a secondary lead compound for structure-activity relationship studies aimed at identifying a suitable compound for positron emission tomography-imaging studies of insoluble Asyn aggregates in Parkinson’s disease. © 2018 American Chemical Society.

Document Type: Article
Source: Scopus

"A HILIC-MS/MS method for simultaneous quantification of the lysosomal disease markers galactosylsphingosine and glucosylsphingosine in mouse serum" (2018) Biomedical Chromatography

A HILIC-MS/MS method for simultaneous quantification of the lysosomal disease markers galactosylsphingosine and glucosylsphingosine in mouse serum
(2018) Biomedical Chromatography, . Article in Press. 

Sidhu, R.a , Mikulka, C.R.b , Fujiwara, H.a , Sands, M.S.a b , Schaffer, J.E.a , Ory, D.S.a , Jiang, X.a

a Department of Medicine Washington University School of Medicine St Louis, MO USA
b Department of Genetics Washington University School of Medicine St Louis, MO USA

Abstract
Deficiencies of galactosylceramidase and glucocerebrosidase result in the accumulation of galactosylsphingosine (GalSph) and glucosylsphingosine (GluSph) in Krabbe and Gaucher diseases, respectively. GalSph and GluSph are useful biomarkers for both diagnosis and monitoring of treatment effects. We have developed and validated a sensitive, accurate, high-throughput assay for simultaneous determination of the concentration of GalSph and GluSph in mouse serum. GalSph and GluSph and their deuterated internal standards were extracted by protein precipitation in quantitative recoveries, baseline separated by hydrophilic interaction chromatography and detected by positive-ion electrospray mass spectrometry in multiple reaction monitoring mode. Total run time was 7 min. The lower limit of quantification was 0.2 ng/mL for both GalSph and GluSph. Sample stability, assay precision and accuracy, and method robustness were demonstrated. This method has been successfully applied to measurement of these lipid biomarkers in a natural history study in twitcher (Krabbe) mice. © 2018 John Wiley & Sons, Ltd.

Author Keywords
Galactosylsphingosine;  Gaucher disease;  Glucosylsphingosine;  Hydrophilic interaction chromatography-tandem mass spectrometry;  Krabbe disease

Document Type: Article in Press
Source: Scopus

"Three-dimensional power doppler evaluation of cerebral vascular blood flow: A novel tool in the assessment of fetal growth restriction" (2018) Journal of Ultrasound in Medicine

Three-dimensional power doppler evaluation of cerebral vascular blood flow: A novel tool in the assessment of fetal growth restriction
(2018) Journal of Ultrasound in Medicine, 37 (1), pp. 139-147. 

Goetzinger, K.R.a , Cahill, A.G.b , Odibo, L.c , Macones, G.A.b , Odibo, A.O.c

a Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Maryland, Baltimore, MD, United States
b Department of Obstetrics and Gynecology, Washington University, St Louis, MO, United States
c Department of Obstetrics and Gynecology, University of South Florida, Tampa, FL, United States

Abstract
Objectives To determine whether fetuses with fetal growth restriction (FGR) are more likely to have abnormal cerebral vascular flow patterns compared to fetuses who are appropriate for gestational age (AGA) when quantified by using 3-dimensional (3D) power Doppler ultrasound. Methods We conducted a prospective cohort study of singleton gestations presenting for growth ultrasound examination between 24 and 36 weeks’ gestation. Patients with FGR (estimated fetal weight < 10th percentile) were enrolled and matched 1:1 for gestational age (±7 days) with AGA fetuses. A standardized 3D power Doppler image of the middle cerebral artery territory was obtained from each patient. The vascularization index (VI), flow index (FI), and vascularization-flow index (VFI) were calculated by the Virtual Organ computer-aided analysis technique (GE Healthcare, Milwaukee, WI). These indices were compared between FGR and AGA fetuses and correlated with 2-dimensional Doppler parameters. Neonatal outcomes were also compared with respect to the 3D parameters. Results Of 306 patients, there were 151 cases of FGR. There was no difference in the VI (6.0 versus 5.7; P = .65) or VFI (2.0 versus 1.8; P = .31) between the groups; however, the FI was significantly higher in FGR fetuses compared to AGA controls (33.9 versus 32.3; P = .009). There was a weak, but significant, negative correlation between the FI and both the middle cerebral artery pulsatility index (r = -0.34; P < .001) and cerebroplacental ratio (r = -0.29; P < .001). Within the FGR group, there was no difference in any of the 3D vascular indices with regard to neonatal outcomes. Conclusions Three-dimensional power Doppler measurement of cerebral blood flow, but not the vascularization pattern, is significantly altered in FGR. This measurement may play a future role in distinguishing pathologic FGR from constitutionally small growth. © 2017 by the American Institute of Ultrasound in Medicine.

Author Keywords
3-dimensional power doppler;  3-dimensional ultrasound;  Fetal growth restriction;  Flow index;  Middle cerebral artery;  Obstetrics;  Vascularization index;  Vascularization-flow index

Document Type: Article
Source: Scopus

"Neurofibromatosis type 1" (2018) Handbook of Clinical Neurology

Neurofibromatosis type 1
(2018) Handbook of Clinical Neurology, 148, pp. 799-811. 

Cimino, P.J.a , Gutmann, D.H.b

a Department of Pathology, University of Washington, Seattle, WA, United States
b Department of Neurology, Washington University School of Medicine, St. Louis, MO, United States

Abstract
The neurofibromatoses are a group of three heterogeneous disorders that include neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis. NF1 is the most common of these three conditions, and represents one of the most frequently diagnosed cancer predisposition disorders involving the nervous system. While NF1 primarily affects the central and peripheral nervous system, multisystem involvement is the rule, with dermatologic, cardiovascular, gastrointestinal, and orthopedic affectation often reported. Importantly, NF1 is a disorder of heterogeneity, such that affected individuals can be variably affected, even within the same family. This heterogeneity also presents significant challenges to the actualization of effective treatments. However, recent studies aimed at understanding the role of the NF1 protein (neurofibromin) as a tumor suppressor have revealed that this profound level of clinical heterogeneity may reflect tissue and region-specific effects, sexually dimorphic influences, and the contribution of germline genetics and genomics. With the availability of accurate preclinical Nf1 small-animal models, human induced pluripotent stem cells, and an efficient clinical trials consortium, we are now uniquely positioned to identify and efficiently evaluate promising therapies for NF1-related medical problems. © 2018 Elsevier B.V.

Author Keywords
astrocytoma;  attention deficit;  glioma;  inherited cancer syndrome;  malignant peripheral nerve sheath tumor;  neurodevelopmental disorder;  neurofibroma;  NF1

Document Type: Book Chapter
Source: Scopus

"Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease" (2018) Alzheimer's and Dementia

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer’s disease
(2018) Alzheimer’s and Dementia, . Article in Press. 

Mattsson, N.a , Groot, C.b , Jansen, W.J.c , Landau, S.M.d , Villemagne, V.L.e , Engelborghs, S.f , Mintun, M.M.g , Lleo, A.h , Molinuevo, J.L.i , Jagust, W.J.d , Frisoni, G.B.j k , Ivanoiu, A.l , Chételat, G.m , Resende de Oliveira, C.n , Rodrigue, K.M.o , Kornhuber, J.p , Wallin, A.q , Klimkowicz-Mrowiec, A.r , Kandimella, R.s , Popp, J.t , Aalten, P.P.c , Aarsland, D.u , Alcolea, D.h , Almdahl, I.S.v , Baldeiras, I.n , van Buchem, M.A.w , Cavedo, E.k x , Chen, K.y , Cohen, A.D.z , Förster, S.aa , Fortea, J.h , Frederiksen, K.S.ab , Freund-Levi, Y.ac , Gill, K.D.s , Gkatzima, O.ad , Grimmer, T.ae , Hampel, H.x af , Herukka, S.-K.ag , Johannsen, P.ah , van Laere, K.ai , de Leon, M.J.aj , Maier, W.ak , Marcusson, J.al , Meulenbroek, O.am , Møllergård, H.M.v , Morris, J.C.an , Mroczko, B.ao , Nordlund, A.q , Prabhakar, S.ap , Peters, O.aq , Rami, L.i , Rodríguez-Rodríguez, E.ar , Roe, C.M.an , Rüther, E.as , Santana, I.n , Schröder, J.at , Seo, S.W.au , Soininen, H.ag , Spiru, L.av , Stomrud, E.a , Struyfs, H.f , Teunissen, C.E.aw , Verhey, F.R.J.c , Vos, S.J.B.c , van Waalwijk van Doorn, L.J.C.ax ay , Waldemar, G.ab , Wallin, Å.K.a , Wiltfang, J.as , Vandenberghe, R.az , Brooks, D.J.ba , Fladby, T.v , Rowe, C.C.e , Drzezga, A.bb , Verbeek, M.M.ax ay , Sarazin, M.bc , Wolk, D.A.bd , Fleisher, A.S.y be bf , Klunk, W.E.z , Na, D.L.au , Sánchez-Juan, P.ar , Lee, D.Y.bg , Nordberg, A.bh , Tsolaki, M.ad , Camus, V.bi , Rinne, J.O.bj , Fagan, A.M.an , Zetterberg, H.bk bl bm bn , Blennow, K.bm bn , Rabinovici, G.D.bo , Hansson, O.a , van Berckel, B.N.M.bp , van der Flier, W.M.b bq , Scheltens, P.b , Visser, P.J.b c , Ossenkoppele, R.a b bp

a Clinical Memory Research Unit, Clinical Sciences Malmö, Lund University, Lund, Sweden
b Department of Neurology and Alzheimer Center, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, Netherlands
c Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University, Maastricht, Netherlands
d Helen Wills Neuroscience Institute, University of California, Berkeley, CA, United States
e Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, Australia
f Reference Center for Biological Markers of Dementia (BIODEM), University of Antwerp, Antwerp, Belgium
g Avid Radiopharmaceuticals, Philadelphia, PA, United States
h Neurology Department, Hospital de Sant Pau, Barcelona, Spain
i Alzheimer’s Disease and Other Cognitive Disorders Unit, IDIBAPS, Clinic University Hospital, Barcelona, Spain
j Memory Clinic and LANVIE- Laboratory of Neuroimaging of Aging, University Hospitals, University of Geneva, Geneva, Switzerland
k Laboratory of Alzheimer’s Neuroimaging and Epidemiology, IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
l Memory Clinic and Neurochemistry Laboratory, Saint Luc University Hospital, Institute of Neuroscience, Université catholique de Louvain, Brussels, Belgium
m Inserm, Inserm UMR-S U1237, Université de Caen-Normandie, GIP Cyceron, Caen, France
n Center for Neuroscience and Cell Biology, Faculty of Medicine, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
o Center for Vital Longevity, School of Behavioral and Brain Sciences, The University of Texas at Dallas, Dallas, TX, United States
p Department of Psychiatry and Psychotherapy, Friedrich-Alexander University of Erlangen- Nuremberg, Erlangen, Germany
q Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden
r Jagiellonian University College of Medicine, Krakow, Poland
s Postgraduate Institute of Medical Education and Research (PGIMER), Department of Biochemistry, Research Block-A, Chandigarh, India
t Department of Psychiatry, Service of Old Age Psychiatry, University Hospital of Lausanne, Lausanne, Switzerland
u Center for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway
v Department of Neurology, Akershus University Hospital, Lørenskog, Norway
w Department of Radiology, Leiden University Medical Center, Leiden, Netherlands
x AXA Research Fund & UPMC Chair, Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Paris 06, Inserm, CNRS, Institut du Cerveau et de la Moelle Épinière (ICM), Département de Neurologie, Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Hôpital Pitié-Salpêtrière, Paris, France
y Banner Alzheimer’s Institute, Phoenix, AZ, United States
z University of Pittsburgh School of Medicine, Department of Psychiatry, Pittsburgh, PA, United States
aa Department of Nuclear Medicine, Technische Universitaet München, Munich, Germany
ab Danish Dementia Research Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
ac Department of Geriatrics, Karolinska University Hospital Huddinge, Section of Clinical Geriatrics, Institution of NVS, Karolinska Institutet, Stockholm, Sweden
ad Third Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece
ae Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universitaet München, Munich, Germany
af Department of Psychiatry, Alzheimer Memorial Center and Geriatric Psychiatry Branch, Ludwig-Maximilian University, Munich, Germany
ag Department of Neurology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland
ah Memory Clinic, Danish Dementia Research Center, Rigshospitalet, Copenhagen, Denmark
ai Department of Imaging and Pathology, Catholic University Leuven, Leuven, Belgium
aj School of Medicine, Center for Brain Health, New York University, New York, NY, United States
ak Department of Psychiatry and Psychotherapy, University of Bonn, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
al Geriatric Medicine, Department of Clinical and Experimental Medicine, University of Linköping, Linköping, Sweden
am Department of Geriatric Medicine, Radboud Alzheimer Center, Radboud University Medical Center, Nijmegen, Netherlands
an Knight Alzheimer’s Disease Research Center, Department of Neurology, Washington University School of Medicine, St Louis, MO, United States
ao Department of Neurodegeneration Diagnostics, Leading National Research Centre in Białystok (KNOW), Medical University of Białystok, Białystok, Poland
ap Department of Neurology, Research Block-A, Chandigarh, India
aq Department of Psychiatry and Psychotherapy, Charité Berlin, German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany
ar Neurology Service, Universitary Hospital Marqués de Valdecilla, CIBERNED, IDIVAL, Santander, Spain
as Department of Psychiatry and Psychotherapy, University Medical Center, Georg-August University, Göttingen, Germany
at Sektion Gerontopsychiatrie, Universität Heidelberg, Heidelberg, Germany
au Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
av Department of Geriatrics-Gerontology-Gerontopsychiatry, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
aw Neurochemistry Laboratory and Biobank, Department of Clinical Chemistry, Amsterdam Neuroscience, VU University Medical Center, Amsterdam, Netherlands
ax Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud Alzheimer Center, Radboud University Medical Center, Nijmegen, Netherlands
ay Department of Laboratory Medicine, Donders Institute for Brain, Cognition and Behaviour, Radboud Alzheimer Center, Radboud University Medical Center, Nijmegen, Netherlands
az Laboratory for Cognitive Neurology and Alzheimer Research Centre KU Leuven, Catholic University Leuven, Leuven, Belgium
ba Division of Neuroscience, Medical Research Council Clinical Sciences Centre, Imperial College London, London, United Kingdom
bb Department of Nuclear Medicine, University of Cologne, Cologne, Germany
bc Neurologie de la Mémoire et du Langage, Centre Hospitalier Sainte-Anne, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
bd Department of Neurology, University of Pennsylvania, Philadelphia, PA, United States
be Eli Lilly, Indianapolis, IN, United States
bf Department of Neurosciences, University of California, San Diego, CA, United States
bg Department of Neuropsychiatry, Seoul National University, College of Medicine, Seoul, South Korea
bh Department NVS, Center for Alzheimer Research, Translational Alzheimer Neurobiology, Karolinska Institutet and Geriatric Medicine, Karolinska University Hospital, Stockholm, Sweden
bi CHRU de Tours, CIC INSERM 1415, INSERM U930, Université François Rabelais de Tours, Tours, France
bj Turku PET Centre and Division of Clinical Neurosciences Turku, University of Turku and Turku University Hospital, Turku, Finland
bk Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, United Kingdom
bl UK Dementia Research Institute, London, United Kingdom
bm Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden
bn Sweden and Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
bo Department of Neurology, Memory and Aging Center, University of California, San Francisco, CA, United States
bp Department of Radiology and Nuclear Medicine, VU University Medical Center, Neuroscience Campus Amsterdam, Amsterdam, Netherlands
bq Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, Netherlands

Abstract
Introduction: Apolipoprotein E (APOE) ε4 is the major genetic risk factor for Alzheimer’s disease (AD), but its prevalence is unclear because earlier studies did not require biomarker evidence of amyloid β (Aβ) pathology. Methods: We included 3451 Aβ+ subjects (853 AD-type dementia, 1810 mild cognitive impairment, and 788 cognitively normal). Generalized estimating equation models were used to assess APOE ε4 prevalence in relation to age, sex, education, and geographical location. Results: The APOE ε4 prevalence was 66% in AD-type dementia, 64% in mild cognitive impairment, and 51% in cognitively normal, and it decreased with advancing age in Aβ+ cognitively normal and Aβ+ mild cognitive impairment (P <.05) but not in Aβ+ AD dementia (P =.66). The prevalence was highest in Northern Europe but did not vary by sex or education. Discussion: The APOE ε4 prevalence in AD was higher than that in previous studies, which did not require presence of Aβ pathology. Furthermore, our results highlight disease heterogeneity related to age and geographical location. © 2018 the Alzheimer’s Association

Author Keywords
Age;  Alzheimer’s disease;  Amyloid;  APOE;  CSF;  Education;  Geographical location;  Mild cognitive impairment;  PET;  Prevalence;  Sex;  Subjective cognitive decline

Document Type: Article in Press
Source: Scopus